Status:
COMPLETED
The Study Will Evaluate the Effect of AZD8683 in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Lead Sponsor:
AstraZeneca
Conditions:
Chronic Obstructive Pulmonary Disease (COPD)
Eligibility:
All Genders
40+ years
Phase:
PHASE2
Brief Summary
The purpose of this study is to investigate effects of inhaled AZD8683 compared to placebo in COPD patients.
Detailed Description
A double-blind, placebo-controlled, randomised, multi-centre, 3-way cross-over, single-dose phase II study to investigate the local and systemic effects of inhaled AZD8683 in patients with chronic obs...
Eligibility Criteria
Inclusion
- Clinical diagnosis of COPD
- Current or ex-smokers
- FEV1 40 - 80% of the predicted normal value (post-bronchodilator) and post-bronchodilator FEV1/FVC \< 70%
Exclusion
- Any clinically significant disease or disorder
- Any clinically relevant abnormal findings at screening examinations
- Family history or presence of glaucoma
- Need of long term oxygen therapy
Key Trial Info
Start Date :
October 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2010
Estimated Enrollment :
28 Patients enrolled
Trial Details
Trial ID
NCT01205269
Start Date
October 1 2010
End Date
December 1 2010
Last Update
March 19 2014
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Bialystok, Poland
2
Research Site
Bydgoszcz, Poland
3
Research Site
Lodz, Poland
4
Research Site
Proszowice, Poland